InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by Skvarka Jan. Insider active across 2 companies, notably Trillium Therapeutics Inc.. Aggregated, 7 disclosures have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €216k. History available since 11 May 2021. The latest transaction was disclosed on 17 June 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 条申报中的 7 条
Skvarka Jan has filed 7 disclosures in total. In the sampled recent filings, the date range runs from 2021-05-13 to 2025-02-04, with EUR 99,493 of purchases and EUR 116,496 of sales. He is a Director at Zentalis Pharmaceuticals, Inc. (XNAS) and President and CEO at Trillium Therapeutics Inc. (XNAS).